The Effects of Pioglitazone on Respiratory Function Test in Patients with Asthma and Type ۲ Diabetes Mellitus- A before –after Study

Objective: Pioglitazone is one of the oral medications of type ۲ diabetes (T۲DM). The purpose of this study was to evaluate the effect of pioglitazone on asthma and diabetes treatment outcomes among patients with concurrent asthma and T۲DM. Materials and Methods: We conducted a quasi-experimental study on ۱۱ patients with concurrent asthma and T۲DM in Yazd Afshar Hospital and Yazd diabetic research center ۲۰۱۴-۲۰۱۷. The inclusion criteria were patients between ۲۰-۶۰ years old, at least one year with concurrent asthma and T۲DM (documented with spirometer, bronchodilator test), ejection fraction more than ۵۰%. Patients who were smoker, on oral corticosteroids, phenobarbital, methotrexate, rifampin, phenytoin and gemfibrozil were excluded. Laboratory tests (FBS, HbA۱c, ۲hpp, leptin), spirometer test, exhaled nitric oxide were done before and after ۱۰ weeks of pioglitazone medication. All patients were visited every two weeks. The before and after pioglitazone treatment differences were checked by paired t-test and Wilcoxon Rank sum test. Results: The mean (± SD) age of participants was ۵۵.۸۱ (±۷.۶۶). The median of differences of leptin (p-value: ۰.۸۸۵), FEV۱ to FVC (P-value: ۰.۱۸۵), FEV۱ (p-value: ۰.۳۸۶), NO (P-value: ۰.۵۷۴), FVC percent (P-value: ۰.۴۷۷), FEV۱ percent (P-value: ۰.۵۱۵) did not differ before and after pioglitazone treatment.    Conclusion: Our finding suggested that pioglitazone may not be effective in the treatment and improvement of respiratory function in T۲DM with concurrent asthma.

کلیدواژه ها:

Bronchial asthma ، Thiazolidinedione ، Diabetes mellitus-type